Answers are grounded in this paper and cite their sources.
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder characterized by progressive motor neuron loss. Although TDP-43 and SOD1 aggregation are major molecular features of ALS, their mechanistic relationship remains unclear. Here, we show that cytoplasmic TDP-43 induced by overexpression or cellular stress promotes SOD1 aggregation and preferentially interacts with trimer-associated SOD1 species. Destabilization of trimeric SOD1 disrupts the SOD1–TDP-43 interaction and reduces TDP-43 aggregation. Genetic depletion of SOD1 ameliorated motor dysfunction and neuronal loss in hTDP-43(+/+) mice, supporting a functional contribution of SOD1 to TDP-43 neurotoxicity. Pharmacological targeting of trimeric SOD1 with Amisodin reduced cytoplasmic TDP-43 accumulation, preserved neurons, improved motor function, and prolonged survival. Amisodin also reduced insoluble SOD1 and TDP-43 and their association in spinal cord tissue. These findings identify trimer-associated SOD1 as a functional modulator of TDP-43 proteotoxicity and support its selective targeting as a therapeutically actionable strategy for molecularly defined forms of TDP-43-associated ALS.
No takes yet. Share an insight, caveat, or question.
Park et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: